AMA Official: Payers Must Craft Clinical Paths To Include Precision Medicine

Payers' growing use of clinical pathways and the country's new focus on precision medicine are not mutually exclusive as long as the pathways are written properly, according to an American Medical Association board member and oncologist who stresses that such pathways need to be flexible and updated frequently or otherwise "you'll be practicing obsolete medicine." The AMA official also called for transparency, saying a patient needs to be aware if their doctor's "arm is being twisted" by a pathway. Her...

Subscriber Login

If you are a subscriber, or you have an active trial subscription, please login here:

Enter your username.
Enter the password that accompanies your username.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.